BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to UM-UC3 cell line is 152
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD44 | 1681 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR and Western Blotting and FACs | NA | 0.6 | 1 | 32661469 |
| CD44 | 1681 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by FACs and IF staining and RT-PCR | NA | 0.6 | 1 | 30397177 |
| CD44 | 1681 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.6 | 1 | 28870814 |
| CD44 | 1681 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.6 | 1 | 31180522 |
| CD44 | 1681 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by IF staining and qRT-PCR | NA | 0.6 | 1 | 26452033 |
| CD44 | 1681 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | Benzidine | SFA followed by Western Blotting | NA | 0.6 | 1 | 33552265 |
| CD44 | 1681 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting | NA | 0.6 | 1 | 33552265 |
| CD44 | 1681 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | FACs | NA | 0.6 | 1 | 29221154 |
| CD44 | 1681 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | FACs | NA | 0.6 | 1 | 29340052 |
| YAP1 | 16262 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.52 | 0.0117 | 30397177 |
| YAP1 | 16262 | HTM/LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics and RT-PCR and Western Blotting | NA | 0.52 | 0.0117 | 30397177 |
| AFF4 | 17869 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.0032 | 32676121 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.684 | 28870814 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.684 | 32661469 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.684 | 31180522 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | Benzidine | SFA followed by Western Blotting | NA | 0.48 | 0.684 | 33552265 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.684 | 33552265 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.684 | 26452033 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | ALDEFLUOR assay followed by SFA | NA | 0.48 | 0.684 | 34405274 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | ALDEFLUOR assay | NA | 0.48 | 0.684 | 27769244 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | ALDEFLUOR assay followed by SFA | NA | 0.48 | 0.684 | 32676121 |
| METTL3 | 17563 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.0011 | 32676121 |
| NANOG | 20857 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 28870814 |
| NANOG | 20857 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 32661469 |
| NANOG | 20857 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.5461 | 31180522 |
| NANOG | 20857 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | Benzidine | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 33552265 |
| NANOG | 20857 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 33552265 |
| NANOG | 20857 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 30397177 |
| NANOG | 20857 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | Cisplatin | qRT-PCR | NA | 0.48 | 0.5461 | 31239709 |
| NANOG | 20857 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 26452033 |
| NANOG | 20857 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SP assay followed by RT-PCR and SFA | NA | 0.48 | 0.5461 | 25020236 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 28870814 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 32661469 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.6448 | 31180522 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | Benzidine | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 33552265 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 33552265 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | Cisplatin | qRT-PCR | NA | 0.48 | 0.6448 | 31239709 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 26452033 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SP assay followed by RT-PCR and SFA | NA | 0.48 | 0.6448 | 25020236 |
| PROM1 | 9454 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.7582 | 28870814 |
| PROM1 | 9454 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.7582 | 32661469 |
| PROM1 | 9454 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.7582 | 31180522 |
| PROM1 | 9454 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by FACs and RT-PCR | NA | 0.48 | 0.7582 | 30397177 |
| PROM1 | 9454 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | Benzidine | SFA followed by Western Blotting | NA | 0.48 | 0.7582 | 33552265 |
| PROM1 | 9454 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.7582 | 33552265 |
| PROM1 | 9454 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | Cisplatin | qRT-PCR | NA | 0.48 | 0.7582 | 31239709 |
| OV6 | NA | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by FACs and IF staining | NA | 0.36 | 0.0011 | 30397177 |
| PDGFB | 8800 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.28 | 0.0032 | 30397177 |
| CCL15 | 10613 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| CCL15 | 10613 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| CCL2 | 10618 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0074 | 30397177 |
| CCL24 | 10623 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| CCL3 | 10627 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| CCL4 | 10630 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| CCL5 | 10632 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0064 | 30397177 |
| CSF1 | 2432 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0032 | 30397177 |
| CSF2 | 2434 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| CSF3 | 2438 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0032 | 30397177 |
| CXCL13 | 10639 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| CXCL9 | 7098 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| GLI1 | 4317 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0308 | 33552265 |
| GLI2 | 4318 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0106 | 33552265 |
| ICAM1 | 5344 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0064 | 30397177 |
| IFNG | 5438 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL10 | 5962 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL11 | 5966 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0032 | 30397177 |
| IL12B | 5970 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL12B | 5970 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL13 | 5973 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL15 | 5977 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| IL16 | 5980 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| IL17A | 5981 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL1A | 5991 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0032 | 30397177 |
| IL1B | 5992 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0074 | 30397177 |
| IL1RN | 6000 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0053 | 30397177 |
| IL2 | 6001 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL4 | 6014 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| IL5 | 6016 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| IL6 | 6018 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0191 | 30397177 |
| IL6 | 6018 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0191 | 30397177 |
| IL7 | 6023 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| IL8 | 6025 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0159 | 30397177 |
| LTA | 6709 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0011 | 30397177 |
| PDGFB | 8800 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0032 | 30397177 |
| SHH | 10848 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0201 | 33552265 |
| SMO | 11119 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0212 | 33552265 |
| TIMP1 | 11820 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0053 | 30397177 |
| TIMP2 | 11821 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0032 | 30397177 |
| TNF | 11892 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| TNFRSF1A | 11916 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by ELISA | NA | 0.28 | 0.0021 | 30397177 |
| ABCB1 | 40 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0604 | 26452033 |
| ABCB1 | 40 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SP assay followed by RT-PCR and SFA | NA | 0.2 | 0.0604 | 25020236 |
| ABCG2 | 74 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | Cisplatin | qRT-PCR | NA | 0.2 | 0.1739 | 31239709 |
| ABCG2 | 74 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.1739 | 26452033 |
| ABCG2 | 74 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SP assay followed by RT-PCR and SFA | NA | 0.2 | 0.1739 | 25020236 |
| ALDH1A2 | 15472 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0117 | 26452033 |
| CD34 | 1662 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | Cisplatin | qRT-PCR | NA | 0.2 | 0.0053 | 31239709 |
| KLF4 | 6348 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0891 | 30397177 |
| KLF4 | 6348 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SP assay followed by RT-PCR and SFA | NA | 0.2 | 0.0891 | 25020236 |
| SOX2 | 11195 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.5695 | 30397177 |
| SOX2 | 11195 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.5695 | 26452033 |
| SOX2 | 11195 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SP assay followed by RT-PCR and SFA | NA | 0.2 | 0.5695 | 25020236 |
| CD24 | 1645 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.12 | 0.456 | 30397177 |
| B4GALNT1 | 4117 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | FACs | NA | 0.12 | 0.0042 | 29221154 |
| CD24 | 1645 | LTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | FACs | NA | 0.12 | 0.456 | 29221154 |
| AMIGO2 | 24073 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| ANKRD1 | 15819 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| AP1S3 | 18971 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| ARHGEF10 | 14103 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30397177 |
| ASAP1 | 2720 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30397177 |
| ATP2A2 | 812 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| ATP8B1 | 3706 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| ATXN1 | 10548 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 30397177 |
| CDC42BPA | 1737 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30397177 |
| CEMIP | 29213 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 30397177 |
| CHD6 | 19057 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| CLSPN | 19715 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30397177 |
| CSE1L | 2431 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30397177 |
| ENDOD1 | 29129 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30397177 |
| FAM13A | 19367 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| FAT1 | 3595 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| FHL2 | 3703 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 30397177 |
| FOS | 3796 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 30397177 |
| GNE | 23657 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 30397177 |
| HAT1 | 4821 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| INSIG1 | 6083 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 30397177 |
| KDELC2 | 28496 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| LAMB1 | 6486 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| LAMC1 | 6492 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30397177 |
| LATS1 | 6514 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30397177 |
| MACC1 | 30215 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| MAN1A1 | 6821 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| MB | 6915 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30397177 |
| MSH6 | 7329 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30397177 |
| ORC1 | 8487 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| PALLD | 17068 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| PDK1 | 8809 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 30397177 |
| PLIN2 | 248 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 30397177 |
| PRKCB | 9395 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30397177 |
| RAPGEF4 | 16626 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30397177 |
| RHOBTB3 | 18757 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 30397177 |
| RNASE4 | 10047 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 30397177 |
| RRM2 | 10452 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| S100A10 | 10487 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| SASS6 | 25403 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30397177 |
| SLC16A7 | 10928 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30397177 |
| SOX17 | 18122 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30397177 |
| SOX9 | 11204 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0244 | 30397177 |
| TACC1 | 11522 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| TEAD1 | 11714 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30397177 |
| TJP3 | 11829 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 30397177 |
| TOR1AIP1 | 29456 | HTM | Bladder Cancer | Transitional Cell Carcinoma | UM-UC3 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 30397177 |